139 related articles for article (PubMed ID: 11438420)
21. Influence of various combinations of mucolytic agent and non-ionic surfactant on intestinal absorption of poorly absorbed hydrophilic compounds.
Takatsuka S; Morita T; Horikiri Y; Yamahara H; Saji H
Int J Pharm; 2008 Feb; 349(1-2):94-100. PubMed ID: 17869034
[TBL] [Abstract][Full Text] [Related]
22. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs.
Sakane T; Akizuki M; Taki Y; Yamashita S; Sezaki H; Nadai T
J Pharm Pharmacol; 1995 May; 47(5):379-81. PubMed ID: 7494186
[TBL] [Abstract][Full Text] [Related]
23. Absorption characteristics of dextrans with different molecular weights from the liver surface membrane in rats: implications for targeting to the liver.
Nishida K; Sato N; Sasaki H; Nakamura J
J Drug Target; 1996; 4(3):141-50. PubMed ID: 8959486
[TBL] [Abstract][Full Text] [Related]
24. Absorption characteristics of model compounds with different molecular weights from the serosal caecal surface in rats.
Nishida K; Nose S; Kuma A; Mukai T; Kawakami S; Nakashima M; Sasaki H; Sakaeda T; Nakamura J
J Pharm Pharmacol; 2002 Jul; 54(7):1005-9. PubMed ID: 12162704
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of the enhancement effect of n-octyl-beta-D-thioglucoside on the transdermal penetration of fluorescein isothiocyanate-labeled dextrans and the molecular weight dependence of water-soluble penetrants through stripped skin.
Ogiso T; Paku T; Iwaki M; Tanino T
J Pharm Sci; 1994 Dec; 83(12):1676-81. PubMed ID: 7534349
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of enhancers to increase nasal absorption using Ussing chamber technique.
Hosoya K; Kubo H; Natsume H; Sugibayashi K; Morimoto Y
Biol Pharm Bull; 1994 Feb; 17(2):316-22. PubMed ID: 7515747
[TBL] [Abstract][Full Text] [Related]
27. Development of a Transnasal Delivery System for Recombinant Human Growth Hormone (rhGH): Effects of the Concentration and Molecular Weight of Poly-L-arginine on the Nasal Absorption of rhGH in Rats.
Kawashima R; Uchida M; Yamaki T; Ohtake K; Hatanaka T; Uchida H; Ueda H; Kobayashi J; Morimoto Y; Natsume H
Biol Pharm Bull; 2016; 39(3):329-35. PubMed ID: 26725528
[TBL] [Abstract][Full Text] [Related]
28. Mucosal drug delivery using cellulose derivatives as a functional polymer.
Suzuki Y; Makino Y
J Control Release; 1999 Nov; 62(1-2):101-7. PubMed ID: 10518641
[TBL] [Abstract][Full Text] [Related]
29. Effect of poly-L-arginine on intestinal absorption of hydrophilic macromolecules in rats.
Yamaki T; Uchida M; Kuwahara Y; Shimazaki Y; Ohtake K; Kimura M; Uchida H; Kobayashi J; Ogihara M; Morimoto Y; Natsume H
Biol Pharm Bull; 2013; 36(3):496-500. PubMed ID: 23257956
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant.
Takatsuka S; Kitazawa T; Morita T; Horikiri Y; Yoshino H
Eur J Pharm Biopharm; 2006 Jan; 62(1):52-8. PubMed ID: 16289777
[TBL] [Abstract][Full Text] [Related]
31. Effects of various absorption promoters on pulmonary absorption of drugs with different molecular weights.
Morita T; Yamamoto A; Hashida M; Sezaki H
Biol Pharm Bull; 1993 Mar; 16(3):259-62. PubMed ID: 7689890
[TBL] [Abstract][Full Text] [Related]
32. Size-dependent dextran transport across rat alveolar epithelial cell monolayers.
Matsukawa Y; Lee VH; Crandall ED; Kim KJ
J Pharm Sci; 1997 Mar; 86(3):305-9. PubMed ID: 9050797
[TBL] [Abstract][Full Text] [Related]
33. Dextran retention in the rat brain following release from a polymer implant.
Dang W; Saltzman WM
Biotechnol Prog; 1992; 8(6):527-32. PubMed ID: 1282018
[TBL] [Abstract][Full Text] [Related]
34. Effects of poly-L-arginine on the permeation of hydrophilic compounds through surface ocular tissues.
Nemoto E; Takahashi H; Kobayashi D; Ueda H; Morimoto Y
Biol Pharm Bull; 2006 Jan; 29(1):155-60. PubMed ID: 16394530
[TBL] [Abstract][Full Text] [Related]
35. Activation of P2Y receptor enhances high-molecular compound absorption from rat ileum.
Kinoshita N; Takahashi T; Tada S; Shinozuka K; Mizuno N; Takahashi K
J Pharm Pharmacol; 2006 Feb; 58(2):195-200. PubMed ID: 16451747
[TBL] [Abstract][Full Text] [Related]
36. Improved nasal bioavailability of FITC-dextran (Mw 4300) from mucoadhesive microspheres in rabbits.
El-Shafy MA; Kellaway IW; Taylor G; Dickinson PA
J Drug Target; 2000; 7(5):355-61. PubMed ID: 10721797
[TBL] [Abstract][Full Text] [Related]
37. Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drug.
Sasaki H; Yamamura K; Tei C; Nishida K; Nakamura J
J Drug Target; 1995; 3(2):129-35. PubMed ID: 7496726
[TBL] [Abstract][Full Text] [Related]
38. Influence of Liver Intoxication by Carbon Tetrachloride or D-Galactosamine on Absorption of Fluorescein Isothiocyanate-Dextran-10 and Other Marker Compounds with Different Molecular Weights from the Rat Liver Surface.
Miyamoto H; Tsuda K; Honda T; Tokunaga A; Fumoto S; Nishida K
Biol Pharm Bull; 2020; 43(2):319-324. PubMed ID: 32009118
[TBL] [Abstract][Full Text] [Related]
39. Ophthalmic preservatives as absorption promoters for ocular drug delivery.
Sasaki H; Nagano T; Yamamura K; Nishida K; Nakamura J
J Pharm Pharmacol; 1995 Sep; 47(9):703-7. PubMed ID: 8583378
[TBL] [Abstract][Full Text] [Related]
40. Regional intestinal absorption of FITC-dextran 4,400 with nanoparticles based on beta-sitosterol beta-D-glucoside in rats.
Nakamura K; Takayama K; Nagai T; Maitani Y
J Pharm Sci; 2003 Feb; 92(2):311-8. PubMed ID: 12532381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
